Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back.

Mendel DB, Cherrington JM, Laird AD.

Clin Cancer Res. 2015 Jun 1;21(11):2415-7. doi: 10.1158/1078-0432.CCR-14-2557.

2.

Comparison of AMG 416 and cinacalcet in rodent models of uremia.

Walter S, Baruch A, Alexander ST, Janes J, Sho E, Dong J, Yin Q, Maclean D, Mendel DB, Karim F, Johnson RM.

BMC Nephrol. 2014 May 19;15:81. doi: 10.1186/1471-2369-15-81.

3.

Translational sciences approach to RSV vaccine development.

Kurzweil V, Tang R, Galinski M, Wang K, Zuo F, Cherukuri A, Gasser RA Jr, Malkin E, Sifakis F, Mendel DB, Esser MT.

Expert Rev Vaccines. 2013 Sep;12(9):1047-60. doi: 10.1586/14760584.2013.824706. Review.

PMID:
24053398
4.

Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients.

Walter S, Baruch A, Dong J, Tomlinson JE, Alexander ST, Janes J, Hunter T, Yin Q, Maclean D, Bell G, Mendel DB, Johnson RM, Karim F.

J Pharmacol Exp Ther. 2013 Aug;346(2):229-40. doi: 10.1124/jpet.113.204834. Epub 2013 May 14.

PMID:
23674604
5.

Influenza virus resistance to neuraminidase inhibitors.

Mendel DB, Sidwell RW.

Drug Resist Updat. 1998;1(3):184-9.

PMID:
17092804
6.

In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors.

Mendel DB, Roberts NA.

Curr Opin Infect Dis. 1998 Dec;11(6):727-32.

PMID:
17035750
7.

Novel robust hepatitis C virus mouse efficacy model.

Zhu Q, Oei Y, Mendel DB, Garrett EN, Patawaran MB, Hollenbach PW, Aukerman SL, Weiner AJ.

Antimicrob Agents Chemother. 2006 Oct;50(10):3260-8.

8.

CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.

Xin X, Abrams TJ, Hollenbach PW, Rendahl KG, Tang Y, Oei YA, Embry MG, Swinarski DE, Garrett EN, Pryer NK, Trudel S, Jallal B, Mendel DB, Heise CC.

Clin Cancer Res. 2006 Aug 15;12(16):4908-15.

9.

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.

Mol Cancer Ther. 2006 Jul;5(7):1774-82.

10.

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.

Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.

Mol Cancer Ther. 2006 May;5(5):1280-9.

11.

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB.

Cancer Res. 2003 Nov 1;63(21):7345-55.

12.

Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.

Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD.

J Pharmacol Exp Ther. 2003 Nov;307(2):476-80. Epub 2003 Sep 9.

PMID:
12966161
13.

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM.

Clin Cancer Res. 2003 Jul;9(7):2755-68.

15.

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM.

Clin Cancer Res. 2003 Jan;9(1):327-37.

16.
17.

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA.

Antiviral Res. 2002 Aug;55(2):307-17.

PMID:
12103431
18.

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.

Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA.

Blood. 2002 Jul 15;100(2):585-93. Erratum in: Blood 2002 Oct 15;100(8):2696.

PMID:
12091352
19.

SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.

Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM.

FASEB J. 2002 May;16(7):681-90.

PMID:
11978732
20.

High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.

Christensen JG, Schreck RE, Chan E, Wang X, Yang C, Liu L, Cui J, Sun L, Wei J, Cherrington JM, Mendel DB.

Clin Cancer Res. 2001 Dec;7(12):4230-8.

21.

The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.

Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM.

Clin Cancer Res. 2000 Dec;6(12):4848-58.

22.

Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM.

Anticancer Drug Des. 2000 Feb;15(1):29-41. Review.

PMID:
10888034
23.

Carbocyclic influenza neuraminidase inhibitors possessing a C3-cyclic amine side chain: synthesis and inhibitory activity.

Lew W, Wu H, Chen X, Graves BJ, Escarpe PA, MacArthur HL, Mendel DB, Kim CU.

Bioorg Med Chem Lett. 2000 Jun 5;10(11):1257-60.

PMID:
10866394
24.
25.

Stereospecific synthesis of a GS 4104 metabolite: determination of absolute stereochemistry and influenza neuraminidase inhibitory activity.

Lew W, Escarpe PA, Mendel DB, Sweeny DJ, Kim CU.

Bioorg Med Chem Lett. 1999 Oct 4;9(19):2811-4.

PMID:
10522696
26.

Neuraminidase inhibitors as anti-influenza virus agents.

Kim CU, Chen X, Mendel DB.

Antivir Chem Chemother. 1999 Jul;10(4):141-54. Review.

PMID:
10480735
27.

The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.

Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH.

Mol Pharmacol. 1999 Sep;56(3):570-80.

PMID:
10462545
28.

Synthesis and evaluation of 1,4,5,6-tetrahydropyridazine derivatives as influenza neuraminidase inhibitors.

Zhang L, Williams MA, Mendel DB, Escarpe PA, Chen X, Wang KY, Graves BJ, Lawton G, Kim CU.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1751-6.

PMID:
10406636
29.

A new series of C3-aza carbocyclic influenza neuraminidase inhibitors: synthesis and inhibitory activity.

Lew W, Wu H, Mendel DB, Escarpe PA, Chen X, Laver WG, Graves BJ, Kim CU.

Bioorg Med Chem Lett. 1998 Dec 1;8(23):3321-4.

PMID:
9873727
30.

Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, Kim CU, Mendel DB.

Antimicrob Agents Chemother. 1998 Dec;42(12):3234-41.

31.

Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors.

Kim CU, Lew W, Williams MA, Wu H, Zhang L, Chen X, Escarpe PA, Mendel DB, Laver WG, Stevens RC.

J Med Chem. 1998 Jul 2;41(14):2451-60.

PMID:
9651151
32.

Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.

Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB.

Antimicrob Agents Chemother. 1998 Mar;42(3):647-53.

33.

Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.

Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, Kim CU.

Antimicrob Agents Chemother. 1998 Mar;42(3):640-6.

34.

Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir.

LoPresti AE, Levine JF, Munk GB, Tai CY, Mendel DB.

Clin Infect Dis. 1998 Feb;26(2):512-3. No abstract available.

PMID:
9502489
35.

In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir).

Xiong X, Flores C, Fuller MD, Mendel DB, Mulato AS, Moon K, Chen MS, Cherrington JM.

Antiviral Res. 1997 Nov;36(2):131-7.

PMID:
9443670
36.
37.

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.

Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, Stevens RC.

J Am Chem Soc. 1997 Jan 29;119(4):681-90.

PMID:
16526129
38.
39.

1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo.

Bischofberger N, Hitchcock MJ, Chen MS, Barkhimer DB, Cundy KC, Kent KM, Lacy SA, Lee WA, Li ZH, Mendel DB, et al.

Antimicrob Agents Chemother. 1994 Oct;38(10):2387-91.

40.

BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription.

Khavari PA, Peterson CL, Tamkun JW, Mendel DB, Crabtree GR.

Nature. 1993 Nov 11;366(6451):170-4.

PMID:
8232556
41.

Genes for the dimerization cofactor of hepatocyte nuclear factor-1 alpha (DCOH) are on human and murine chromosomes 10.

Milatovich A, Mendel DB, Crabtree GR, Francke U.

Genomics. 1993 Apr;16(1):292-5.

PMID:
8486378
42.

Identity of 4a-carbinolamine dehydratase, a component of the phenylalanine hydroxylation system, and DCoH, a transregulator of homeodomain proteins.

Citron BA, Davis MD, Milstien S, Gutierrez J, Mendel DB, Crabtree GR, Kaufman S.

Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11891-4.

43.

Characterization of a cofactor that regulates dimerization of a mammalian homeodomain protein.

Mendel DB, Khavari PA, Conley PB, Graves MK, Hansen LP, Admon A, Crabtree GR.

Science. 1991 Dec 20;254(5039):1762-7.

PMID:
1763325
44.

Independent regulation of HNF-1 alpha and HNF-1 beta by retinoic acid in F9 teratocarcinoma cells.

Kuo CJ, Mendel DB, Hansen LP, Crabtree GR.

EMBO J. 1991 Aug;10(8):2231-6.

45.
46.

HNF-1, a member of a novel class of dimerizing homeodomain proteins.

Mendel DB, Crabtree GR.

J Biol Chem. 1991 Jan 15;266(2):677-80. Review. No abstract available.

47.
48.

HNF-1 shares three sequence motifs with the POU domain proteins and is identical to LF-B1 and APF.

Baumhueter S, Mendel DB, Conley PB, Kuo CJ, Turk C, Graves MK, Edwards CA, Courtois G, Crabtree GR.

Genes Dev. 1990 Mar;4(3):372-9.

49.

Glucocorticoid receptors and actions.

Munck A, Mendel DB, Smith LI, Orti E.

Am Rev Respir Dis. 1990 Feb;141(2 Pt 2):S2-10. Review. No abstract available.

PMID:
2178511
50.

Evidence for a glucocorticoid receptor cycle and nuclear dephosphorylation of the steroid-binding protein.

Mendel DB, OrtĂ­ E, Smith LI, Bodwell J, Munck A.

Prog Clin Biol Res. 1990;322:97-117. Review. No abstract available.

PMID:
2406740

Supplemental Content

Loading ...
Support Center